Gain in US prostate cancer sales disappoints Telix investors
MELBOURNE: ASX-listed biotech Telix Pharmaceuticals has reported a near 40 per cent sales ...
To read the full story...SUBSCRIBE NOWExisting Subscribers Login Below:
Log In
